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ABSTRACT 
Temporomandibular joint disorder is characterized by peripheral and central sensitization 
of trigeminal nociceptive neurons.  Although CGRP is implicated in the development of 
central sensitization by stimulating glial activation via its receptor, the mechanism by 
which CGRP promotes and maintains sensitization of trigeminal nociceptive neurons is 
not well understood.  The goal of my study was to investigate the role of calcitonin gene-
related peptide (CGRP) on the initiation and maintenance of a nocifensive withdrawal 
response to mechanical stimulation following activation of primary trigeminal sensory 
neurons.  For my studies, I used adult male Sprague Dawley rats that were injected with 
CGRP alone or co-injected with inhibitors and determined changes in nocifensive 
behavior and inflammatory proteins.  Intrathecal injection of CGRP increased nocifensive 
responses to mechanical stimulation up to 48 hours and this stimulatory effect was 
blocked by the antagonist peptide CGRP8-37 and a protein kinase A inhibitor.  Results 
from my cellular studies provide evidence that elevated levels of CGRP in the spinal cord 
can promote bidirectional signaling within the trigeminal system, a novel finding that 
helps to explain how central sensitization can lower the activation threshold of primary 
nociceptors in TMD patients.      
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INTRODUCTION 
 
Temporomandibular Joint Disorder 
The temporomandibular or jaw joint is comprised of bilateral hinges on the side 
of the face, and allows the motions necessary for speech, eating, and yawning. The hinges 
themselves are an articulation between the glenoid fossa of the temporal bone of the skull 
and the condylar processes of the mandible. Surrounding the joint is a fibrous membrane 
called the capsule. The fiber extends between the two articular surfaces, forming the 
temporomandibular disc, and posterior to the hinge splits vertically; this region is called 
the retrodiscal tissue. Two synovial sacs lubricate the joint, above and below the disc. 
Many muscles and ligaments attach to the mandible, and the retrodiscal tissue is heavily 
innervated. Given the complexity of this structure coupled with the frequency of jaw use, 
disorders involving this joint are quite common.  
Temporomandibular disorder (TMD) is a condition involving pain in muscles of 
mastication and the temporomandibular joints, often accompanied by limited jaw 
movement (Dworkin et al., 1990; Poveda Roda et al., 2007; Manfredini et al., 2011). 
Temporomandibular joint disorders (TMJD) specifically affect the joint rather than the 
muscles. TMJD is more often unilateral and more frequently associated with trauma than 
the more general TMD, which may be associated with stress or entirely idiopathic.  
Nomenclature of these disorders is not universal, and some professionals may simply 
split TMD into categories of myogenous (muscle-related) or arthrogenous (joint-related).   
Millions of American adults experience symptoms associated with TMD, such as jaw 
pain, restriction of movement, swelling, headache, and tinnitus (Bevilaqua Grossi et al. 
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2009; Mujakperuo et al., 2010; Ohrbach et al., 2011).  Men and women are both 
impacted, with the highest incidence of pain during adolescence (Manfredini et al., 2011). 
TMD symptoms are often comorbid with other disorders that are indicative of a 
systemically sensitized state, such fibromyalgia (Light et al., Aaron et al., 2000; Dahan et 
al., 2015; Furquim et al., 2015). 
 
Trigeminal Nerve and Trigeminal Ganglion 
The trigeminal nerve is the most complex of the cranial nerves (Shankland, 2000). 
It originates in a sensory root as well as a motor root at the border of the pons, and is 
further divided into three major sections: the ophthalmic, maxillary, and mandibular.  The 
ophthalmic branch, also referred to as V1, provides only sensory input and is responsible 
for innervating the scalp, forehead, upper eyelid, eyebrow, eye, portions of the nasal 
cavity, the tentorium cerebelli, posterior flax cerebri and dura mater (Shankland, 2001a).  
Headache disorders can be primarily attributed to this portion of the trigeminal nerve. 
The second division is also purely afferent in function and intermediate in size.  It 
innervates the maxillary bone and the midfacial region, including the skin of the 
midfacial regions, lower eyelid, side of nose and upper lip, the mucous membrane of the 
nasopharynx, maxillary sinus, soft palate, palatine tonsil, roof of the mouth, maxillary 
gingivae, and maxillary teeth (Shankland, 2001b).  It is responsible for transmission of 
pain arising in the sinus cavities. The third and largest division of the nerve is the 
mandibular, which performs both afferent and efferent functions.  It is composed of two 
separate roots, a large sensory root and a smaller motor root.  The sensory root innervates 
the skin of the temporal region and lower third of the face, lower lip, and ear, the mucous 
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membrane of the anterior two-thirds of the tongue and mouth floor, the muscles of the 
first brachial arch, and the teeth and gingivae of the mandible (Shankland, 2001c).  The 
small motor root supplies efferent innervation to the muscles of the first brachial arch 
which consist of the muscles of mastication, the tensors veli palatini and tympani, the 
mylohyoid muscle, and anterior belly of the digastrics muscle.  This portion of the nerve 
is activated during TMD (Sessle, 2011). 
The cell bodies of the sensory fibers making up the trigeminal nerve are located in 
the trigeminal ganglion (TG). These neurons fall into two basic morphological types 
known as small dark (SD) and large light (LL) neurons.  Large light neurons give rise to 
myelinated Aδ fibers, which transmit signal more quickly.  Unmyelinated, slower 
transmitting C-fibers extend from small dark neurons.  Both of these neuron types are 
pseudounipolar, with two diverging axonal branches (Fig. 1).  The peripheral process 
extends to the cranial or facial area the neuron innervates, while a central process ascends 
to the spinal trigeminal nucleus and synapses with second order neurons (Devor, 1999; 
Rathee et al., 2002).  The trigeminal ganglion is also populated by two types of 
supportive glial cells. Schwann cells provide the myelination to neuronal fibers, 
contributing to increased signal speed, while satellite glia modulate the environment 
surrounding individual neuronal cell bodies and modulate their excitability state.  As seen 
in Figure 2, a neuron and its surrounding satellite glia comprise a single functional unit, 
which develops during the first weeks after birth and functions to maintain homeostasis 
(Hanani, 2005; Durham and Garrett, 2010a).  Importantly, increased neuron-glia 
communication via paracrine signaling and gap junctions are associated with diseases of 
the head and face involving trigeminal nerve activation (Durham and Garrett, 2010b). 
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Trigeminal Nociception Pathway 
Sensory fibers exit the trigeminal ganglion to synapse with second order neurons 
in the trigeminal nuclei (Bereiter et al., 2000; Takeshita et al., 2001). The most inferior of 
the three sensory nuclei is the spinal trigeminal nucleus (STN), and receives information 
from both neuronal types in all three branches of the trigeminal nerve. This nucleus can 
be subdivided into the subnuclei, from rostral to caudal, oralis, interpolaris, and caudalis 
(Davies et al.; 2010). The trigeminal nucleus caudalis (TNC) is the most inferior and 
processes nociceptive signal from the jaws, teeth, and face (Wilcox et al., 2015). From 
the TNC, second order neurons relay nociceptive signal to the thalamus, where third 
order neurons transmit the information to the somatosensory cortex (Shankland, 2000; 
Bernstein and Burstein, 2012). 
Similar to the cellular organization of the TG, the STN is comprised of both 
neuronal and glial cells (Milligan and Watkins, 2009; Woolf, 2011). The glial cells 
located within the central nervous system include astrocytes, microglia, and 
oligodendrocytes. Astrocytes modulate the extracellular environment by regulating the 
concentrations of ions and neurotransmitters, control energy supply to neurons, and 
regulate synaptic formation and transmission (Watkins, et al. 2007).  Microglia are 
resident phagocytic cells of the brain and spinal cord and play a key role in the 
development of chronic inflammatory and pain states. They express major 
histocompatibility complex class II receptors and function to monitor the environment for 
potential damage caused by increased expression of cytokines and chemokines.  Once 
activated, microglia may migrate, proliferate, release inflammatory mediators, and alter 
receptor expression (Raivich, 2005; Ji et al., 2013; Lee, 2013).  Both astrocytes and 
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microglia may be induced by neurotransmitters or other inflammatory molecules into an 
active state that results in the release of pro-inflammatory mediators (Miller et al., 2009; 
Ikeda et al., 2012). 
 
Peripheral and Central Sensitization 
Sensitization is a characteristic of neurons that have undergone molecular changes 
to reduce the amount of mechanical, chemical, or thermal stimuli required to cause their 
activation. In current pain models, peripheral sensitization of primary nociceptive 
neurons is thought to promote and sustain central sensitization of second order neurons 
involved in pain transmission to the thalamus (Sessle, 2011; Bernstein and Burstein, 
2012).  Within the trigeminal ganglion, satellite glia may become activated following 
neuronal dissemination of pain signals in response to chemical, thermal, or mechanical 
stimuli within peripheral tissues. Once activated, satellite glial cells produce molecules 
such as cytokines and chemokines, which have the potential to alleviate or exacerbate 
inflammation in the peripheral nervous system (Gosselin et al., 2010; Vause and Durham, 
2010; Villa et al., 2010).  Pro-inflammatory signaling from glia in combination with 
consistent nociceptive signals from the peripheral nervous system may chronically alter 
the excitability of second order neurons, leading to long-term hypersensitivity to noxious 
stimuli (Durham and Garrett, 2010b).  This hypersensitivity might manifest as ion 
channels opening at lower voltages, excitatory ion channels staying open longer, or 
inhibitory ion channels taking longer to become active. Development of this sensitized 
state (central sensitization) leads to a decrease in the activation threshold and is a key 
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pathological feature of many trigeminal nerve mediated diseases including migraine, 
TMD, and allergic rhinitis (Woolf, 2011). 
Peripheral sensitization results from the interaction of nociceptors with 
inflammatory substances released when tissue is damaged or inflamed (Sessle, 2011). 
This sensitization state may reduce the threshold of depolarization required for generation 
of action potentials within nociceptive neurons.  Such electrical activity that facilitates 
depolarization subsequently promotes release of peptides and neurotransmitters that 
function to protect the site from further injury through development of hyperalgesia, 
defined as increased sensitivity to painful stimuli, and allodynia, which is the experience 
of pain arising from a non-painful stimulus, such as a light touch.  In addition release of 
these pro-inflammatory molecules promotes healing by increasing blood flow, vascular 
permeability, and recruitment of white blood cells.  While transient peripheral 
sensitization of nociceptive neurons that lasts for 24-48 hours is considered a normal 
physiological response, prolonged sensitization (>1 week) can lead to pathology.  The 
different molecules comprising this inflammatory mixture may be promising targets for 
pain management strategies when peripheral sensitization becomes a chronic state.    
Central sensitization refers to an increase in the excitability state of neurons in the 
dorsal horn of the spinal cord following high levels of activity in the nocifensive afferents 
(Ikeda et al., 2012; Furquim et al., 2015). This results in normally subthreshold activity 
becoming adequate to generate action potentials in the dorsal horn, further promoting 
hyperalgesia (increased pain sensitivity).  Once central sensitization has been triggered by 
nociceptor activity, non-nociceptive afferent nerves may produce activation of the dorsal 
horn, thus causing allodynia (painful response to non-painful stimuli) that functions to 
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extend the receptive field in peripheral tissues.  In acute models of pain, peripheral 
sensitization has been shown to promote cellular changes that mediate central 
sensitization (Dodick and Silberstein, 2006; Taylor and Corder, 2014).  However, in 
chronic pain states, central sensitization persists in the absence of evidence of peripheral 
tissue damage.  A major focus of my thesis research was to determine if central 
sensitization can mediate cellular changes to promote sensitization of peripheral 
nociceptive neurons.    
 
Molecules Implicated in Promoting and Maintaining Neuronal Sensitization 
Hypersensitivity in the central nervous system is dependent on both inter and 
intra-cellular signaling. Within cells, protein signaling may impact transcription, mRNA 
translation, and sensitivity of ion channels, production of neurotransmitter, and other 
functions that directly control sensitivity.  One protein that is directly implicated in the 
initiation and maintenance of a prolonged sensitized state in the spinal cord is calcitonin 
gene-related peptide (CGRP), a 37 amino-acid neuropeptide formed through alternative 
splicing of the calcitonin gene (Rosenfeld et al., 1983; Benemei et al., 2009; Seybold, 
2009).  It is found in both central and peripheral neurons and was initially shown to 
function as a powerful vasodilator (Brain et al., 1985).  More recently, increased levels of 
CGRP have been reported in serum and saliva of migraine patients (Bellamy et al., 2006; 
Cady et al., 2009) and in the capsule of TMJD patients (Holmlund et al., 1991; Spears et 
al., 2005).  CGRP is now known to play a central role in promoting inflammation and 
nociception via its ability to promote increased blood flow, protein plasma extravasation, 
recruitment of immune cells, and  decrease of the threshold for depolarization in 
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nociceptive neurons and associated glial cells (Durham and Vause, 2010). There are two 
isoforms of the peptide in both rats and humans,  and  (Fischer and Born, 1985).  The 
 form is the predominant form found in trigeminal nerves, and will be referred to 
hereafter simply as CGRP.  Its receptor complex is comprised of three separate proteins: 
a G-protein-coupled receptor (GPCR), calcitonin receptor-like receptor (CLR) and an 
accessory protein, receptor activity-modifying protein 1 (RAMP1) that confers ligand-
binding specificity (Benemei et al., 2007; Durham, 2008) . Following binding of CGRP 
to its receptor, the membrane bound enzyme adenylate cyclase is activated and causes an 
increase in the intracellular levels of the second messenger cAMP.   
Protein Kinase A (PKA) is an extremely versatile kinase whose activity is 
dependent on the presence of cyclic adenosine monophosphate (cAMP) in the cell (Kim 
et al., 2006). Cyclic AMP binds to PKA’s regulatory subunit, altering its affinity and 
causing it to dissociate, thus exposing PKA’s catalytic subunit. The catalytic subunit may 
then phosphorylate a variety of target proteins, including CREB, a transcription factor 
implicated in neuroplasticity.  In addition, elevated PKA levels in the cytosol are 
correlated with sensitization and activation of nociceptive neurons and glial cells via 
modulation of receptor expression and ion channel activity (Sun et al., 2004).  CGRP is 
also known to cause activation of mitogen activated protein (MAP) kinases in trigeminal 
neurons, which are associated with increased inflammation and nociception and are used 
as biomarkers of neuronal and glial cell activation (Cady et al., 2011).  Similar to PKA, 
MAP kinases are activated through a G-protein coupled receptor (GPCR) mediated 
mechanism, triggering a kinase cascade that can also impact transcription factors 
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including CREB, leading to increased synthesis of pro-inflammatory genes that contain 
CRE cis regulatory elements (e.g., CGRP, cytokines, chemokines) (Ji et al., 2009).  
The expression of cytokines, a broad category of small signaling proteins is 
known to be regulated by CGRP, PKA, and MAP kinases (Miller et al., 2009; Vause and 
Durham, 2010, 2012; Ji et al., 2013).  This large family includes chemokines, 
interleukins, and tumor necrosis factor, which function to modulate inflammatory 
responses to changes in chemical stimuli caused by infection or tissue injury.  Cytokines 
may be both pro and anti-inflammatory.  Pro-inflammatory cytokines include IL-1β, IL-6, 
and TNF-α, all of which have been implicated in mechanisms of pathological pain 
(Kress, 2010; Song et al., 2014).  Changes in cytokine expression and signaling by 
various cell types represent one mechanism by which normal inflammation due to an 
insult might transition to a maladaptive pain state.  Within the central nervous system, 
astrocytes and microglia are known to synthesize and release cytokines to control the 
environment around neurons while in the trigeminal ganglion, satellite glial cells perform 
that function (Takeda et al., 2007; Damodaram et al., 2009; Gosselin et al., 2010; Ji et al., 
2013). 
 
Hypothesis and Goals of Thesis Research 
Within the pain community, peripheral sensitization is traditionally considered to 
be the cause of central sensitization. However, it is possible that within some pathological 
conditions, central mechanisms may lower the activation threshold of primary 
nociceptive neurons within the trigeminal ganglion.  For example, elevated levels of 
CGRP in the cerebral spinal fluid have been reported during and in between migraine 
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episodes. I hypothesize that elevated levels of CGRP with the cerebral spinal fluid of the 
upper spinal cord will promote sensitization of both central and peripheral nociceptive 
neurons, and thus provide novel evidence of bidirectional signaling within the trigeminal 
system. 
Goals: 
1.  Determine if increased levels of CGRP in the upper spinal cord can lead to peripheral 
sensitization of primary trigeminal neurons to mechanical stimulation. 
 
2.  Investigate the mechanism by which CGRP promotes peripheral sensitization using 
inhibitors of the CGRP receptor and downstream signaling proteins. 
 
3.  Directly demonstrate bidirectional signaling from central processes of trigeminal 
neurons to ganglion cell bodies using a retrograde dye. 
 
4.  Explore the intracellular pathways involved in CGRP-mediated peripheral 
sensitization using immunohistochemistry. 
 
5. Use a protein array to identify potential cytokines upregulated by CGRP-mediated 
pathways. 
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Figure 1. Schematic depiction of a pseudounipolar neuron that are found in a trigeminal 
ganglion.  Satellite glial cells, which completely surround the neuronal cell body to create 
a functional unit, modulate neuronal excitability. Schwann cells are responsible for the 
production of myelin, which functions to speed nerve conduction.  The neuron extends 
two processes from its cell body.  One provides innervation of peripheral tissues in the 
head and face, while the other process projects into the upper spinal cord and synapses 
with second order nociceptive neurons. 
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Figure 2. Identification of the neuronal and glial cell nuclei in adult rat trigeminal 
ganglion.  (A) Longitudinal sections of the entire ganglion from an untreated animal were 
stained with DAPI to identify all nuclei (40x magnification). (B) Magnification (100x) of 
a neuron containing a section of the V3 branch of (A).  (C) Magnification (400x) of a 
neuron-satellite glial cell cluster from (B).  (D) An enlarged area from (C) showing a 
single neuron surrounded by satellite glial cells.  The vertical arrow is pointing towards 
the nucleus of a single neuron while the horizontal arrows identify the nuclei of satellite 
glial cells. 
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MATERIALS AND METHODS 
 
Animals and Reagents  
Animal studies were approved by the Institutional Animal Care and Use 
Committee (Protocol #14-038.0 approved on August 16th, 2014) at Missouri State 
University. All studies were conducted in compliance with all established guidelines in 
the National Institutes of Health and the Animal Welfare Act. An effort was made to 
reduce the number of animals used in the study as well as to minimize suffering. Adult, 
male Sprague-Dawley rats (350-500 g) were obtained from Charles River Laboratories 
Inc. (Wilmington, MA) or purchased from Missouri State University (internal breeding 
colonies).  All animals were housed in clean, plastic standard rat cages (VWR, West 
Chester, PA) in an animal holding room on a 12-hour light/dark cycle starting at 7 A.M. 
with ambient temperature maintained from 22-24°C and access to food and water ad 
libitum. Animals were acclimated to the environment for a minimum of 1 week upon 
arrival prior to use. 
Stock solutions of CGRP or CGRP8-37 (American Peptide Company, Sunnyvale, 
CA) were both prepared at a concentration of 1 mM in 0.9% saline solution (Fisher-
Scientific, Fair Lawn, NJ) and frozen in aliquots of 5 μl at -20°C. The PKA inhibitor 
KT5720 (Tocris, Bristol, UK) was prepared at a stock concentration of 1 mM in DMSO 
(Sigma-Aldrich, St. Louis, MO) and frozen in aliquots of 5 μl at -20°C. On the day of the 
experiment, an aliquot of 1 mM CGRP was thawed and diluted in 0.9% sterile saline to a 
concentration of 1 μM either alone or in solution with one of the two inhibitors. The 
inhibitors CGRP8-37 and KT5720 were prepared in 0.9% saline solution with CGRP at 
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concentrations of 5 μM and 500 nM, respectively.  The retrograde labeling dye Fast Blue 
(Polysciences Inc., Warrington, PA) was diluted to a concentration of 4% in sterile PBS 
with 1 μM CGRP.  
 
Behavioral Testing 
Male Sprague-Dawley rats were used to determine whether injection with vehicle 
control or CGRP would cause the rats to develop a nocifensive response to mechanical 
stimulation. The procedure used was based on a study from our laboratory that validated 
using the Durham Animal Holder (Ugo Basile, Varese Lakes, Italy) to facilitate 
measurement of the nocifensive responses to mechanical stimulation in the head and face 
of rats by holding them still in an optimal position without exerting undue stress on the 
animal. (Garrett et al., 2012; Cady et al., 2014; Hawkins et al., 2015).  Prior to testing, the 
rats were acclimated by guiding them into the holding device as shown in Figure 3. The 
animals were secured in the holder for 5 minutes using a plastic blockade inserted behind 
the hindpaws.  To minimize false responses during von Frey testing, a pipette tip was 
used to touch the animal’s head and face to acclimate the rats to having the cutaneous 
tissue over the masseter muscle touched with a filament. This was done for the three 
consecutive days prior to testing with von Frey filaments.  During this acclimation 
period, if a rat appeared to be unwilling to go into the device or was continuously moving 
and shifting within the device, the animal was removed from the study. 
Following acclimations, nocifensive thresholds were determined in response to a 
series of calibrated von Frey filaments (North Coast Medical, Inc., Gilroy, CA; 60, 100, 
180, grams) applied to the cutaneous tissue over the masseter muscle. A positive response 
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was recorded when an animal visibly flinched away from a filament prior to it bending, 
while pressure was being applied. Each filament was applied five times on each side, and 
the data reported is the average number of withdrawals from those ten applications. If a 
filament failed to elicit more than three responses on a given side, a more forceful 
filament was applied in the same manner. The 100 gram filament was chosen for 
subsequent studies since baseline positive responses to this force were consistently less 
than one bilaterally, while the 180 gram filament regularly provoked more than three out 
of five nocifensive head withdrawal responses per side.  
The day after establishing mechanical sensitivity baselines, the animals were 
anesthetized by inhalation of 5% isoflurane.  Thorough anesthesia was confirmed by 
examining blink reflexes. The animals were then injected intrathecally using a 26 ½ 
gauge needle (Becton Dickinson, Franklin Lakes, NJ) and a 50 L Hamilton syringe 
(Hamilton Company, Reno, NV) between the occipital bone and the first cervical 
vertebrae (C1) with CGRP (1 μM; 20 μl) either alone, or co-injected with CGRP8-37 (5 
μM; 20 μl) or KT 5720 (500 nM; 20 μl), a selective signaling inhibitor of PKA. Controls 
were injected with saline alone, and naïve controls received no treatment.  These 
concentrations were selected based on previously published studies in which this 
concentration of CGRP elicited cellular changes within the trigeminal system (Cady et 
al., 2011). Mechanical testing for nocifensive reactions at 2 h, 24 h, 48 h, and 72 h time-
points after injections was done in the same way baselines were established.  A summary 
of my experimental design is shown in Figure 4.   
For the mechanical stimulation studies, the data are reported as the mean number 
of withdrawal responses ± the standard error of the mean (S.E.M.) to 100 g of force at 
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each condition and time point. Subsequent analysis was then performed on data with n = 
6 or greater for each experimental condition using a mixed design repeated measures 
ANOVA to test for general statistical significance, followed by a paired-samples t-test to 
find changes within subjects, and an independent samples t-test to test for differences 
between groups. Statistical significance was set at P < 0.05. 
 
Immunohistochemistry, Cytokine Array, and Retrograde Dye Studies 
To investigate changes in protein levels, injections were performed as described 
above with CGRP (1 μM; 20 μl) alone or co-injected with CGRP8-37 (5 μM; 20 μl) or a 
selective signaling protein inhibitor of PKA (KT 5720). The brainstem and upper spinal 
cord (6 mm posterior to the obex) were removed at 2, 48, or 72 hours after injection. The 
spinal cord was split in half in the sagittal plane. One side was snap frozen in liquid 
nitrogen for protein extraction and protein array analysis. The other half was placed in 
4% paraformaldehyde to be used for immunohistochemistry. 
For the immunohistochemical analysis, spinal cord tissue was incubated in 4% 
paraformaldehyde at 4°C for approximately 24 hours. Tissues were then placed in 12.5% 
sucrose at 4°C, until they sank. They were then moved to 25% sucrose and left for at least 
8 hours, until they sank.  At this point they were stored at -20°C until they were ready for 
use. To section tissues, tissues were embedded in Optimal Cutting Temperature 
compound (OCT; Sakura Finetek, Torrance, CA). Transverse sections 14 µm in thickness 
were taken between 4 and 5 mm caudal to the obex of the upper spinal cord, using a 
cryostat set at -24⁰C.  Sections were placed on Superfrost Plus slides (Fisher Scientific, 
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Pittsburg, PA) with the caudal side of the spinal cord in contact with the glass and stored 
at -20⁰C.  
Slides populated with sections were rehydrated for 5 minutes in phosphate 
buffered saline (PBS), then permeabilized in a solution of 0.1% Triton X-100 in 5% 
donkey serum (Jackson ImmunoResearch Laboratories, West Grove, PA) for 20 minutes 
at room temperature.  Following this incubation, sections were thoroughly rinsed with 
PBS and incubated with primary antibodies for proteins of interest (Table 1) for either 3 
hours at room temperature or overnight in a humidified chamber at 4⁰C.  After this 
incubation was complete, the sections were incubated in solutions of secondary 
antibodies for one hour at room temperature, then mounted in Vectashield medium (H-
1200) containing 4’,6-diamidino-2-phenylindole (DAPI; Vector Laboratories, 
Burlingame, CA) to stain cell nuclei in preparation of viewing using fluorescent 
microscopy. 
 Images were taken using a Zeiss Axiocam mRm camera mounted on a Zeiss 
Imager Z2 fluorescent microscope with an Apotome.   Image acquisition was performed 
using Zeiss Zen 2012 software (Thornwood, NY).  Once immunohistological images of 
the spinal cord were obtained, relative levels of the proteins of interest were analyzed 
using image J software.   Fluorescent intensity was measured in ten rectangular regions in 
laminas I-III in the medullary horn.  Average intensity from acellular regions was then 
measured and subtracted from the average intensity in the laminas.  All data are presented 
as mean fold-change from the average naïve value ± S.E.M.  Values were pooled across 
time points for control conditions. Tissues from animals injected with CGRP were kept 
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separated by time point and compared to pooled control values. Analysis was performed 
by a one-way ANOVA with a Games-Howell post-hoc due to unequal variances. 
For the cytokine arrays, tissues from the upper spinal cord were snap frozen after 
first being rinsed with ice-cold PBS to remove blood from neural tissue.  Clean tissues 
were homogenized in 500 µl of RIPA buffer (Thermo Scientific) with a plastic pestle and 
then allowed to incubate for 30 minutes on ice. Samples were then sonicated briefly. 
Finally, the tubes were centrifuged at 4° C for 20 minutes, at a relative centrifugal force 
of 10,000 x g to produce a pellet containing the cell membranes and debris from the cells 
as well as a supernatant containing the intracellular proteins of interest. The supernatant 
was divided into aliquots in 500 µl tubes and stored at -20° C for array analysis.  The 
amount of total protein was determined by the BCA method and for each experimental 
condition 200 µg of protein was used for analysis.  The relative levels of 19 cytokines 
were measured in control or CGRP-treated animals using RayBio Rat Cytokine Antibody 
Array 1.1 (RayBiotech, Norcross, GA).  Detection of immunoreactivity was performed 
using a chemiluminescent peroxidase substrate (Pierce ECL Plus Western Blotting 
Substrate, Thermo Scientific, Waltham, MA). Silver halide film (Kodak BioMax Film, 
Sigma-Aldrich, St. Louis, MO) was exposed to the chemiluminescent blots for several 
different exposure times to provide a range of dot densities for semi-quantitative analysis.   
For the cytokine arrays, densitometric analysis was performed essentially as 
described in previous publications from our lab with data points excluded from analysis if 
they were undistinguishable from background signal by the software (Vause and Durham, 
2010, 2012, Cady et al., 2013, Hawkins et al., 2015).  Results were analyzed using the 
protein array analyzer macro for Image J software (Schneider et al., 2012). A 2D rolling 
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ball background subtraction with a radius of 40 was used to normalize background levels. 
The pixel density of three pairs of dots was determined from blots with a short (10 
seconds), medium (30 seconds), or long (2 minutes) exposure time based on their relative 
intensity. Three different exposure times were used so that the dots would be dark enough 
to measure density without being overexposed. Circles with a diameter of 7 pixels were 
placed over each dot on the protein array to determine pixel density.  For analysis, the 
average pixel density of the background was subtracted from the pixel density for each 
dot.  Each experimental condition was repeated in two independent experiments done in 
duplicate.  Reported levels are the average fold-change value ± standard error when 
compared to the average control level, which was made equal to one.    
For the retrograde dye study, 50 μL of Fast Blue and 1 µM CGRP diluted in PBS, 
was injected into the intrathecal space between the occipital bone and C1 while the 
animal was anesthetized with 3.5% isoflurane in oxygen.  Animals were allowed to 
recover as normal.  Seven days later, the animals were euthanized via asphyxiation with 
carbon dioxide (CO2) followed by decapitation. The brainstem and upper spinal cord (6 
mm posterior to the obex) and trigeminal ganglia were removed and prepared for 
immunohistochemistry.  Trigeminal ganglia were incubated in 4% paraformaldehyde, 
followed by 12.5% sucrose and 25% sucrose as described above. Following these 
incubations, ganglia were frozen, dorsal side up, in OCT.  Longitudinal sections (14 μm) 
were prepared and mounted on Superfrost Plus slides. In preparation for viewing, tissues 
were rehydrated with PBS and then mounted in Vectashield medium without DAPI to 
identify cells within the ganglion that exhibit fluorescence from retrograde transport of 
the dye from the spinal cord.    
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Table 1.  Summary of Antibodies and Conditions Used for Immunohistochemistry. 
 
 
Protein Dilution Company Incubation 
Time 
Incubation 
Temperature 
GFAP 1:5,000 Abcam 3 hours 20-22°C 
Iba1 1:500 Abcam 3 hours 20-22°C 
NeuN 1:1,000 Millipore 3 hours 20-22°C 
P-ERK 1:500 Bioworld Overnight 20-22°C 
PKA 1:500 Abcam 3 hours 4°C 
Alexa 488 1:200 Life Technologies 1 hour 20-22°C 
Alexa 567 1:200 Life Technologies 1 hour 20-22°C 
Alexa 647 1:200 Life Technologies 1 hour 20-22°C 
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Figure 3. Devices used for behavioral testing. An animal restrained in the Durham holder 
(A) and an enlarged image of the holder showing cut out area that is used to gain access 
to specific regions in the rat’s head and face (A’). Example of von Frey filaments used in 
my study (B). From left to right: 60 grams, 100 grams, and 180 grams. 
  
A
B
A’
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Figure 4.  Schematic of experimental timeline for behavioral studies. 
  
Day 0
Injections + 
2 hr von 
Frey test
Day 1 von 
Frey test
Day 1
Day 2 von 
Frey test
Day 2
Day 3 von 
Frey test + 
euthanasia
Day 3Acclimations
Days 1-3
Days 
4-5
Rest
Testing begins
Basal von Frey 
test
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RESULTS 
 
Behavioral Testing  
Behavioral studies were used to determine whether CGRP injection into the 
cerebrospinal fluid of the upper spinal cord would produce a nocifensive response 
analogous with that reported in acute episodes in patients with TMD.  Rats were defined 
as hypersensitive when their response to the filament of interest reached an average of 2.5 
head withdrawals in response to mechanical stimulation over both TMJ.  The filament 
determined to be the filament of interest had a pressure of 100 g, due to the observation 
that this force rarely elicited a positive response from naïve animals, while the proceeding 
force of 180 g almost always resulted in nocifensive reactions. The average number of 
withdrawals by control animals for both the left and right side to the 100 g filament 2 
hours, 24 hours, and 48 hours in naïve animals and post saline injection can be seen in 
Figure 5. Naïve controls withdrew from the 100 g filament on average 0.7 times at 
baseline, 0.3 times at 2 hours, 0.9 times at 24 hours, and 1.3 times at 48 hours. Animals 
injected with saline alone withdrew from the 100 g filament an average of 0.7 times at 
baseline, 1.1 times 2 hours following injection, 1.3 times 24 hours following injection, 
and 0.9 times at 48 hours. The average number of withdrawal responses at baseline (basal 
condition) for the CGRP animals was similar to both naïve and saline control values (Fig. 
6). There was no significant difference in basal responses between conditions. In contrast, 
increased nocifensive responses were observed in animals injected with 1 µM CGRP at 2 
hour, 24 hours, and 48 hours.  However 72 hours post injection, the levels were again 
similar to control.  Animals injected with CGRP withdrew from the 100 g filament an 
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average of 0.7 times at baseline, 2.7 times 2 hours following injection, 2.7 times 24 hours 
following injection, 3.3 times 48 hours after injection, and 1.29 times 72 hours following 
injections.  
Statistical analysis of nocifensive withdrawals to the 100 g filament showed no 
difference between animals of different conditions prior to the treatment administration. 
Additionally, after injections, naïve and vehicle-injected controls did not show a 
significant difference in withdrawal rate at any time point.  In contrast, the number of 
nocifensive withdrawals of animals injected with CGRP was significantly different from 
naïve (p = 0.022) and vehicle (p = 0.015) controls at 2 hours. Nocifensive withdrawal 
differences were still significant from vehicle (p = 0.036) and naïve (p = 0.017) at 24 
hours. At 48 hours, the difference between CGRP and naïve animals remained significant 
(p = 0.038), as well as differences between animals injected with CGRP versus vehicle 
(p= 0.002). At day 3, animals injected with CGRP no longer showed differences in 
nocifensive responses compared to vehicle controls (p = 0.904) or naïve controls (p = 
0.091).  Taken together, elevated levels of CGRP in the upper spinal cord were shown to 
transiently increase the number of nocifensive head withdrawals in response to 
mechanical stimulation of trigeminal neurons. 
To begin to determine the signaling pathways involved in CGRP mediated 
increases in nociception, animals were co-injected with CGRP and an inhibitor to the 
CGRP receptor or an inhibitor to the downstream signaling enzyme PKA (Fig. 7). Co-
injecting CGRP with CGRP8-37 suppressed the stimulatory effect of CGRP on the number 
of nociceptive withdrawals to the 100 g filament. Animals co-injected with CGRP and 
CGRP8-37 responded on average 0.7 times under basal conditions, 1.3 times 2 hours post-
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injection, 1.4 times at 24 hours and 0.83 times at 48 hours. Animals co-injected with 
CGRP and the PKA inhibitor KT5720 reacted to the 100 g filament an average of 0.5 
times basally, 2.6 times 2 hours after injection, and 0.86 times at both 24 and 48 hours.  
Injection of KT5720 along with CGRP resulted in a time-sensitive amelioration of 
changes in nocifensive withdrawals. Two hours after injection, there was no significant 
difference between animals injected with CGRP alone and those who also received the 
inhibitor. However, at 24, 48, and 72 hours, animals that were simultaneously injected 
with CGRP and KT5720 reacted to the 100 g filament significantly less than those 
injected with only CGRP. Consistently, animals injected with the inhibitor exhibited a 
significant change from naïve and vehicle controls at the 2 hour time point, but failed to 
show significant difference for any subsequent time points. In addition, animals injected 
with both KT5720 and CGRP showed significant changes in nocifensive responses at two 
hours when compared back to their own baseline responses (p = 0.012), but failed to 
show significant changes at any other time point compared to basal levels.  
 
Immunohistochemistry in the Upper Spinal Cord 
Secondary antibodies were applied alone to tissues to evaluate their selectivity. 
The upper spinal cord tissue containing the medullary horn was dissected out and 
incubated with fluorescently-labeled secondary antibodies to determine the specificity of 
each of the antibodies used in my study.  As seen in Figure 8, incubation with each of the 
secondary antibodies alone (without primary antibody) resulted in a diffuse staining 
pattern consistent with low level non-specific background staining of the upper spinal 
cord tissue.   
  26 
 
PKA levels were evaluated between different treatment conditions. A summary of 
the fold-change ± SEM in the relative intensity of PKA immunostaining compared to 
naïve levels (mean made equal to one) for each condition is shown in Table 2. In naïve 
animals, low levels of PKA immunostaining were detected in the upper spinal cord tissue 
(Fig. 9). The level of PKA staining was not significantly different from naïve controls in 
animals injected with sterile saline alone (0.97 fold, p = 0.989). At 2 hours, CGRP-
injected animals exhibited an increase in PKA immunostaining intensity (2.43 fold, p < 
0.001) in comparison with both naïve and vehicle controls. This increase was still present 
at 48 hours post-injection (2.43 fold, p < 0.001), while saline controls still showed no 
changes from naïve (1.15 fold, p = 0.142), as seen in Figure 10. At 72 hours, PKA levels 
in CGRP-injected animals remained significantly elevated when compared to naïve (1.82 
fold, p < 0.001) and vehicle (p =0.004) control levels (Fig. 11). Saline injection at this 
point still failed to elicit any significant change from naïve levels of PKA (1.04 fold, p = 
0.924).  
 Levels of GFAP were compared between treatment conditions to evaluate 
changes in astrocyte activity in the spinal cord. A summary of the fold-change ± SEM in 
the relative intensity of GFAP immunostaining compared to naïve levels (mean made 
equal to one) for each condition is shown in Table 3. Low levels of glial fibrillary acidic 
protein (GFAP) are present in upper spinal cord tissues of naïve animals. Injection of 
sterile saline alone was sufficient to increase expression of GFAP in astrocytes in the 
upper spinal cord (1.62, p < 0.001) two hours post-injection, as seen in Figure 12. 
Animals injected with CGRP were significantly different from naïve levels as well (p < 
  27 
0.001). CGRP injected animals did not show significant changes compared with vehicle 
controls at 2 hours. Forty-eight hours after injection, GFAP levels in upper spinal cord 
from vehicle control animals were no longer significantly different from levels in naïve 
tissues (1.21 fold, p = 0.538, Fig. 13). In contrast, levels of GFAP in animals injected 
with CGRP were significantly higher from both naïve and vehicle controls at this time 
point (3.03 fold, p < 0.001). Seventy-two hours after injection, vehicle controls did not 
exhibit any significant change from naïve levels (1.23 fold, p = 0.240). Spinal cords from 
rats injected with CGRP still showed significantly different GFAP levels to those injected 
with saline (1.93 fold, p < 0.001), as seen in Figure 14.  
 Relative levels of Iba1 were assessed in the spinal cord to evaluate whether there 
were changes in microglia activity in response to CGRP. A summary of the fold-change 
± SEM in the relative intensity of Iba1 immunostaining compared to naïve levels (mean 
made equal to one) for each condition is shown in Table 4. Relative levels of Iba1, a 
marker for active microglia, were compared between upper spinal cord tissues from rats 
under various treatments as described above.  Injection of sterile saline alone elicited a 
statistically significant change from naïve levels of Iba1 (1.41 fold, p = 0.018). Levels of 
Iba1 in spinal cord taken from animals injected with CGRP at two hours post-injection 
(Fig. 15) showed a modest increase of 1.3-fold over naïve that was statistically different 
from levels in naïve (p = 0.010)  but not saline (p = 0.974) controls. This increase 
lessened to 1.24-fold and was no longer significant from naïve controls in tissues 
harvested 48 hours after injections (p = 0.184, Fig. 16). Vehicle controls were not 
significantly different from naïve levels at 48 hours after injections. (p = 0.139). These 
trends persisted at the 72 hour time point, when neither animals that received saline alone 
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nor CGRP showed significant changes in Iba1 expression from naïve animals (p = 0.328, 
p = 0.257, respectively. Fig. 17).  
 
Cytokine Arrays 
To test whether intrathecal administration of CGRP could promote temporal 
changes in cytokine expression, tissues from the upper spinal cord (obex to a distance 6 
mm posterior to the obex) were isolated from control animals and animals receiving 
intrathecal injection of CGRP. As seen in Figure 18, 1 µM CGRP caused a> 2-fold 
increase in the relative expression levels of 19 cytokines (out of 29 total cytokines) when 
compared to control levels 2 hours post injection and all remained elevated above control 
after 24 hours. The greatest increases were seen with CNTF and Fractalkine (> 4 fold) at 
the 2 hour time point.  These data provide evidence of coordinated regulation of 
cytokines by CGRP within the upper spinal cord tissue.  
 
P-ERK  
 To investigate if elevated CGRP levels in the spinal cord could mediate changes 
in gene expression peripherally, immunohistochemistry was performed to examine the 
localization of the active, phosphorylated form of extracellular signal-regulated kinase (p-
ERK) in the neurons. While p-ERK immunostaining was observed in the cytosol of 
neuronal cell bodies in naïve animals, the active form was more localized in the nuclei of 
trigeminal neurons in animals 2 hours post CGRP injection (Fig. 19).  ERK expression in 
neuronal nuclei was confirmed through tissue morphology and its co-localization with the 
NeuN antibody (data not shown). 
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Fast Blue 
To test whether sensitization elicited centrally could promote changes in cell 
bodies peripherally, Fast Blue dye was co-injected with CGRP. This structure is small 
enough to be endocytosed in the terminals of primary neurons. Increased signaling in the 
central nervous system lead to larger amounts of the dye taken up that then have the 
potential to be transported to the peripheral nervous system. The fluorescent dye Fast 
Blue was observed in the cell body of trigeminal neurons and satellite glial cells 5 days 
after intrathecal co-injection of Fast Blue and 1 µM CGRP.  The diffuse pattern of 
fluorescence is indicative of the presence of active signaling between neurons and their 
related satellite glia. The presence of the dye in the ganglia shows the potential for small 
molecules present centrally to move in a retrograde manner to the peripheral nervous 
system, indicating a possible mechanism by which cellular events centrally might elicit 
changes peripherally. 
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Table 2. Summary of fold changes in PKA levels in the upper spinal cord in response to 
CGRP.  All data are reported as the average fold change when compared to levels in 
naïve animals, which was made equal to one ± the standard error of the mean. 
 
 
Time After 
Injection 
Vehicle Fold 
Change ± SEM 
CGRP Fold 
Change ± SEM 
2 hr 0.97 ± 0.06 2.43 ± 0.11#+ 
48 hr 1.16 ± 0.04 2.43 ± 0.15#+ 
72 hr 1.05 ± 0.05 1.82 ± 0.14#+ 
 
* = significantly different from naïve  
# = significantly different from vehicle 
+ = significantly different from naïve  
Significant is defined by p < 0.05 
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Table 3. Summary of fold changes in GFAP levels in the upper spinal cord in response to 
CGRP. All data are reported as the average fold change when compared to levels in naïve 
animals, which was made equal to one ± the standard error of the mean. 
 
 
Time After 
Injection 
Vehicle Fold 
Change ± SEM 
CGRP Fold 
Change ± SEM 
2 hr 1.62 ± 0.11* 1.88 ± 0.13 
48 hr 1.21 ± 0.14 3.03 ± 0.17#+ 
72 hr 1.23 ± 0.10 1.93 ± .20#+ 
 
* = significantly different from naïve  
# = significantly different from vehicle 
+ = significantly different from naïve  
Significant is defined by p < 0.05 
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Table 4. Summary of fold changes in Iba1 levels in the upper spinal cord in response to 
CGRP.  All data are reported as the average fold change when compared to levels in 
naïve animals, which was made equal to one ± the standard error of the mean. 
 
 
Time After 
Injection 
Vehicle Fold 
Change ± SEM 
CGRP Fold 
Change ± SEM 
2 hr 1.41 ± 0.11* 1.33 ± 0.09* 
48 hr 0.75 ± 0.08 1.24 ± 0.09 
72 hr 0.83 ± 0.06 1.10 ± .13 
 
* = significantly different from naïve  
Significant is defined by p < 0.05 
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Figure 5. No significant difference in the number of nocifensive withdrawals to the 100 g 
filament between naïve animals and those injected intrathecally with sterile saline. 
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Figure 6. Increased number of nocifensive withdrawals to the 100 g filament compared 
with basal, naïve, and vehicle levels at 2, 24, and 48 hours after CGRP injection. 
Nocifensive responses returned to normal by 72 hours.  
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Figure 7. Decrease in number of nocifensive responses to the 100 g filament in animals 
that received inhibitor co-injections in a time-dependent manner. Significance from naïve 
and vehicle control animals is marked with an asterisk. Animals that received KT5720 
responded significantly less than animals that received CGRP alone at 24 and 48 hours 
post-injection. 
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Figure 8. No detectable staining pattern observed in tissues that were incubated with 
secondary antibodies only.  A representative spinal cord tissue was stained with the 
nuclear dye DAPI and a 50x multi-image alignment photograph was taken of the whole 
tissue to show morphology (top left). A representative DAPI-stained 200x image of the 
medullary horn of the upper spinal cord tissue is shown in the top right panel.  The same 
section was stained with the Life Technologies AlexaFluor secondaries specified in Table 
2. A merged image of secondary antibodies and DAPI staining is shown in the bottom 
right panel.  
DAPI
488 R 568 M
647 G Merged
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Figure 9. Increased expression of PKA in upper spinal cord in response to CGRP 
injection two hours prior.  Images (200x) from a representative region of the medullary 
horn stained with DAPI is shown in the top panels, while PKA immunostaining in naïve 
animals (left), vehicle controls (center) and treated animals (right) is seen in the second 
row panels. A merged image of the same sections co-stained with PKA and DAPI are 
shown in the third row.  The bottom panels are a merged image of PKA and NeuN 
staining, showing the localization of PKA expression relative to neuronal cell bodies.  
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Figure 10. Increased expression of PKA in upper spinal cord in response to CGRP 
injection 48 hours prior.  Images (200x) from a representative region of the medullary 
horn stained for expression of PKA in naïve animals (left), vehicle controls (center) and 
treated animals (right). The same sections shown in the top panels were stained with the 
nuclear dye DAPI.  A merged image of the PKA and DAPI staining is shown in the 
bottom panels. 
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Figure 11. Increased expression of PKA in upper spinal cord in response to CGRP 
injection 72 hours prior.  Images (200x) from a representative region of the medullary 
horn stained for expression of PKA in naïve animals (left), vehicle controls (center) and 
treated animals (right). The same sections shown in the middle panels were co-stained 
with the nuclear dye DAPI.  A merged image of the PKA and DAPI staining is shown in 
the bottom panels 
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Figure 12. Increased expression of GFAP in upper spinal cord compared to naïve control 
in response to CGRP injection two hours post injection.  Images (200x) from a 
representative region of the medullary horn stained for expression of GFAP in naïve 
animals (left), vehicle controls (center) and treated animals (right). The same sections 
shown in the middle panels were co-stained with the nuclear dye DAPI.  A merged image 
of the GFAP and DAPI staining is shown in the bottom panels. 
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Figure 13. Increased expression of GFAP in upper spinal cord in response to CGRP 
injection 48 hours prior.  Images (200x) from a representative region of the medullary 
horn stained for expression of GFAP in naïve animals (left), vehicle controls (center) and 
treated animals (right). The same sections shown in the middle panels were co-stained 
with the nuclear dye DAPI.  A merged image of the GFAP and DAPI staining is shown in 
the bottom panels. 
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Figure 14. Increased expression of GFAP in upper spinal cord in response to CGRP 
injection 72 hours prior.  Images (200x) from a representative region of the medullary 
horn stained for expression of GFAP in naïve animals (left), vehicle controls (center) and 
treated animals (right). The same sections shown in the middle panels were co-stained 
with the nuclear dye DAPI.  A merged image of the GFAP and DAPI staining is shown in 
the bottom panels 
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Figure 15. Increased expression of Iba1 in upper spinal cord in response to CGRP or 
saline injection two hours prior.  Images (200x) from a representative region of the 
medullary horn stained for expression of Iba1 in naïve animals (left), vehicle controls 
(center) and treated animals (right). The same sections shown in the top panels were co-
stained with the nuclear dye DAPI.  A merged image of the Iba1 and DAPI staining is 
shown in the bottom panels. 
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Figure 16. No change in expression of Iba1 in upper spinal cord in response to CGRP 
injection 48 hours prior.  Images (200x) from a representative region of the medullary 
horn stained for expression of Iba1 in naïve animals (left), vehicle controls (center) and 
treated animals (right). The same sections shown in the top panels were co-stained with 
the nuclear dye DAPI.  A merged image of the Iba1 and DAPI staining is shown in the 
bottom panels. 
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Figure 17.  No significant change in expression of Iba1 in upper spinal cord in response 
to CGRP injection 72 hours prior.  Images (200x) from a representative region of the 
medullary horn stained for expression of Iba1 in naïve animals (left), vehicle controls 
(center) and treated animals (right). The same sections shown in the top panels were co-
stained with the nuclear dye DAPI.  A merged image of the Iba1 and DAPI staining is 
shown in the bottom panels. 
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Figure 18. Intrathecal injection of CGRP caused prolonged elevation of cytokine 
expression in the upper spinal cord tissue.  CGRP was administered intrathecally rostral 
to C1 and spinal cord tissues were isolated at 2 or 24 hours for analysis using a rat 
cytokine antibody array.  (n = 2 independent experiments done in duplicate)  
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Figure 19.  Elevated levels of CGRP stimulate increased expression of p-ERK in 
trigeminal ganglion neurons.  The panels on the left are representative images from naïve 
animals while the ones on the right are from CGRP treated animals.  The number of 
neurons exhibiting nuclear localization of the active form of ERK was increased 
compared to naïve controls 2 hours post intrathecal injection of CGRP.  
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Figure 20.  Evidence of bidirectional signaling within the trigeminal system:  central to 
peripheral retrograde transport.  The fluorescent dye Fast Blue was localized in the cell 
body of neurons and satellite glial cells 5 days after co-injection of CGRP and Fast Blue 
in the upper spinal cord.  Horizontal arrows identify neuronal cell bodies while vertical 
arrows identify satellite glial cells. 
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DISCUSSION 
 
CGRP Promotes Trigeminal Nociceptor Sensitization 
Elevated levels of CGRP are implicated in the development and maintenance of 
central sensitization and an enhanced pain state characterized by hyperalgesia and 
allodynia in diseases involving trigeminal nerves including TMD and migraine (Sun et 
al., 2003; Sun et al., 2004; Seybold, 2009).  However, whether elevated CGRP levels in 
the upper spinal cord could cause peripheral sensitization of primary nociceptive 
trigeminal neurons that provide sensory innervation to tissues in the head and face had 
not been investigated.  I found that administration of CGRP in the upper spinal cord 
resulted in a significant increase in the number of nocifensive head withdrawals in 
response to mechanical stimulation of the trigeminal nerve.  Importantly, this finding is in 
agreement with data from human studies in which both TMD and migraine patients 
report increased sensitivity to mechanical pressure applied to the head and face during an 
attack (Burstein et al., 2015; Dahan et al., 2015; Furquim et al., 2015).  Under normal 
physiological conditions, the increase in pain sensitivity provides a protective mechanism 
that helps to prevent the individual from doing further damage to the tissue.  As shown in 
my study, the enhanced nocifensive response was seen as early as 2 hours post 
administration and this sensitized state was maintained for at least 48 hours with 
resolution by 72 hours post intrathecal CGRP injection. This finding is in agreement with 
the time course reported by migraine and TMD patients during an acute attack in which 
the severe pain and enhanced sensitivity is rarely sustained past 72 hours.  My finding 
that elevated levels of CGRP within the upper spinal cord can lower the activation 
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threshold of trigeminal primary sensory neurons to mechanical stimulation provide the 
first direct evidence, to my knowledge, to help explain the association of CGRP and the 
enhanced pain states reported by TMD and migraine patients.    
 
 CGRP-Mediated Sensitization Involves PKA 
The physiological and cellular effects of CGRP are mediated via activation of the 
CGRP receptor, which is expressed on primary trigeminal neurons that synapse in the 
outer lamina of the spinal cord and the associated glial cells, astrocytes and microglia 
(Edvinsson et al., 1997; Durham, 2008; Durham and Vause, 2010).  To demonstrate the 
specificity of the CGRP-mediated response, I co-administered CGRP with the truncated 
CGRP molecule (CGRP8-37), which acts as a competitive inhibitor of the CGRP receptor 
(Chiba et al., 1989; Recober and Russo, 2009).  I found that CGRP8-37 could inhibit the 
stimulatory effect of CGRP on nociception at each of the time points included in my 
study.  These results provide evidence that blocking the CGRP receptor within the spinal 
cord is sufficient to suppress the initiation and maintenance of peripheral sensitization of 
trigeminal nociceptive neurons.  Following binding of CGRP to its G-protein-coupled 
receptor, there is an increase in adenylate cyclase activity within those cells leading to an 
increase in the intracellular level of the secondary messenger cyclic adenosine 
monophosphate (cAMP).  Elevated levels of cAMP then cause an increase in expression 
of the active form of the signaling kinase PKA via binding to an allosteric site in the 
protein.  Once activated, PKA promotes cellular changes via phosphorylation of proteins 
that function to regulate the excitability state of neurons and glial cells, and the synthesis 
and release of pro-inflammatory molecules that sustain central sensitization.  Somewhat 
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surprisingly, I found that co-injection of the PKA inhibitor (KT 5720) with CGRP did not 
inhibit trigeminal sensitization to mechanical stimulation at the 2 hour time point but did 
suppress mechanical sensitivity 24 and 48 hours post injection.  While these results 
appear contradictory at first, a possible explanation is that CGRP in the spinal cord elicits 
an immediate increase in nuclear p-ERK in primary neurons, independent of PKA 
activity in the central nervous system. The maintenance of the sensitization, however, is 
likely mediated by central PKA expression at least partially in astrocytes. Taken together, 
my data support the notion that the initial increase in neuronal sensitivity is due to 
cellular changes within the primary neurons while the more sustained sensitized state is 
attributable, at least in part, to activation of glial cells.   
Data from my behavioral studies suggest the involvement of PKA activation in 
mediating the downstream stimulatory effects of CGRP.  To determine if elevated CGRP 
levels in the spinal cord could stimulate increased expression of PKA in neurons and glial 
cells within the medullary horn, I used immunohistochemistry to directly study changes 
in PKA levels.  The rationale for investigating PKA is based on evidence that PKA 
activation is associated with development of central sensitization (Levy and Strassman, 
2002; Hu et al., 2003; Kohno et al., 2008). Based on colocalization of PKA with both 
NeuN and GFAP, I found that PKA levels were significantly increased in both second 
order neurons and glial cells in response to CGRP at 2 hours post injection when 
compared to levels in naïve and vehicle treated animals.  PKA levels remained 
significantly elevated at 48 and 72 hours post injection.  This finding is suggestive that, 
although a CGRP-mediated enhancement in nociceptive sensitivity had resolved by 72 
hours, the neurons and glia within the upper spinal cord retained a level of sensitization 
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referred to as cellular memory.  In this state, a lower level of inflammatory stimuli is 
required to cause activation of those cells.  My finding is in agreement with other studies 
that have shown that elevated levels of PKA are involved in the initiation and 
maintenance of peripheral and central sensitization (Aley and Levine, 1999; Hu et al., 
2003; Hucho and Levine, 2007; Seybold, 2009).  The modulatory effects of PKA are 
thought to involve activation of pathways and transcription factors that regulate the 
expression and activity level of ion channels and receptors in nociceptive neurons and 
increase expression of pro-inflammatory molecules in both neurons and glial cells 
(Seybold, 2009).  Furthermore, activation of the PKA pathway within the spinal cord has 
been shown to lead to central sensitization of second order nociceptive neurons and can 
promote bidirectional sensitization of primary nociceptors (Kohno et al., 2008; Cady et 
al., 2011; Hawkins et al., 2015).  More specifically, increased levels of PKA in the spinal 
cord are involved in the development of central sensitization by increasing the activity of 
glutamate receptors expressed on second order neurons that facilitate pain transmission 
(Aley and Levine, 1999; Hucho and Levine, 2007; Latremoliere and Woolf, 2009).  In 
addition, activation of intracellular signaling pathways involving PKA are reported to 
promote the induction and maintenance of central sensitization and persistent pain by 
phosphorylation of ion channels (Fitzgerald et al., 1999; Bhave et al., 2002; Han et al., 
2005), and increasing expression of  pro-inflammatory and pro-nociceptive cytokine 
genes that contain CRE regulatory sites within their promoters (Kawasaki et al., 2004).  
PKA activity also leads to increased phosphorylation and hence activation of ERK in 
nociceptive neurons (Kohno et al., 2008).  Furthermore, blocking PKA signaling results 
in reduction of inflammation-induced hyperalgesic behaviors (Malmberg et al., 1997; 
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Aley and Levine, 1999).  Taken together, my findings provide evidence to further support 
the notion that PKA signaling plays a central role in mediating the stimulatory effects of 
CGRP, and thus is likely to be an important signaling pathway in promoting central and 
peripheral sensitization associated with TMD and migraine.    
 
CGRP Induces Astrocyte Activation and Increased Cytokine Expression 
Activation of the glial cells, including astrocytes and microglia, within the spinal 
cord is known to contribute to prolonged sensitization of nociceptive neurons and 
development of chronic pain states (Ren and Dubner, 1999; DeLeo and Yezierski, 2001; 
Watkins et al., 2001; Wieseler-Frank et al., 2004; Guo et al., 2007; Ren and Dubner, 
2008; Gosselin et al., 2010).  In support of this notion, I observed increased levels of 
immunoreactivity of GFAP in spinal cord sections of CGRP injected animals, indicating 
the activation of astrocytes.  The observed increase in GFAP occurred at the 2 hour time 
point with levels greatest after 48 hours post injection, and remained significantly 
elevated even at 72 hours, a finding similar to my PKA results.  In contrast, CGRP did 
not cause an increase in the expression of Iba1 in microglia when compared to control 
levels at any of the time points.  It is now generally accepted that hyperactivation of 
spinal glia, in particular astrocytes, contribute to the development and maintenance of 
inflammatory pain (Aschner, 2000; Svensson et al., 2003; Raghavendra et al., 2004) and 
the development of central sensitization. Astrocytes are thought to promote and sustain 
sensitization of peripheral and central neurons through the release of cytokines.  
Interestingly, activation of the PKA signaling pathway is known to promote synthesis and 
secretion of cytokines from activated glia cells (Miller et al., 2009).  Cytokines can act 
  54 
directly to sensitize nociceptors and increase neuronal sensitivity to chemical, thermal, 
and mechanical stimuli by increasing the expression of receptors and ion channels 
involved in pain and analgesia (Ren and Torres, 2009; Uceyler et al., 2009).  Towards 
this end, in preliminary studies, I found that CGRP could induce the expression of almost 
20 different cytokines in the upper spinal cord.  The observed increased expression level 
of several cytokines would further suggest that elevated levels of CGRP leads to 
sensitization of the trigeminal system by increasing neuron-glial cell interactions in the 
spinal cord.  Based on my data, I propose that elevated CGRP levels in the spinal cord 
functions to facilitate enhanced central neuron-glia interactions and cytokine release and 
therefore stimulate key cellular events known to promote and maintain central 
sensitization and peripheral sensitization.   
 
CGRP Promotes Bidirectional Signaling within the Trigeminal System 
To investigate a possible mechanism by which elevated CGRP levels in the spinal 
cord could lead to an increased nocifensive response in primary trigeminal nociceptive 
neurons indicative of peripheral sensitization, I determined changes in the level of the 
MAP kinase ERK in trigeminal neurons.  Intrathecal CGRP caused a large increase in the 
nuclear localization of active, phosphorylated form of ERK (P-ERK) in the cell bodies of 
trigeminal neurons throughout the entire ganglion 2 hours post injection.  In contrast in 
naïve control ganglion, P-ERK was mostly localized in the cytosol of neurons.  Increased 
levels of the P- ERK are associated with a sensitized state of primary nociceptive neurons 
by upregulating ion channel expression and activity of membrane receptor expression 
(Cheng and Ji, 2008a; Cheng and Ji, 2008b; Ji et al., 2009; Takeda et al., 2009). Further 
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evidence of the importance of MAP kinases in the induction of peripheral sensitization 
and persistent pain is provided by results from studies in which blocking MAP kinase 
activity with specific inhibitors was reported to suppress nociceptive responses and 
sensitization (Milligan et al., 2003; Tsuda et al., 2004; Ji et al., 2009).  Results from my 
study provide evidence that CGRP promotes changes in neurons within the trigeminal 
ganglia that are consistent with development and maintenance of peripheral sensitization 
of primary nociceptors.  These data are in agreement with a previous study from our 
laboratory that demonstrated that nicotine could mediate an increase in neuron-glial 
signaling within the upper spinal cord leading to peripheral sensitization of primary 
trigeminal nociceptive neurons (Hawkins et al., 2015).  Taken together, these findings 
provide evidence to support the notion of bidirectional signaling with the trigeminal 
system. 
To demonstrate that CGRP can promote retrograde signal transduction from the 
spinal cord to neuronal cell bodies located in the trigeminal ganglion, the retrograde dye 
Fast Blue was co-injected in the upper spinal cord and 5 days later its location observed 
using immunoflouresent microscopy.  I found that Fast Blue was not only detected in the 
cell bodies of neurons but was also observed at higher levels in satellite glial cells.  These 
data for the first time provide direct evidence of bidirectional signaling from the 
cerebrospinal fluid to neuronal cell bodies and then movement through gap junctions to 
satellite glial cells.  We can only speculate on the mechanism by which Fast Blue is 
retrogradely delivered to the cell body but is likely to involve endocytosis and the 
formation of transport vesicles.  Taken together, my results support the idea that elevated 
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levels of CGRP within the spinal cord can facilitate sensitization of primary trigeminal 
neurons by mediating direct changes in trigeminal nociceptive neurons.   
 
Summary and Future Directions 
I propose the following model to explain how elevated levels of CGRP within the 
upper spinal cord could cause a decrease in the activation threshold to mechanical stimuli 
in primary trigeminal neurons.  CGRP would promote a rapid change in primary 
trigeminal neurons that are associated with initiation of peripheral sensitization via 
activation of the ERK signaling pathway and increased neuron-satellite glial cell 
interactions.  The ability of the PKA inhibitor to ameliorate latent, but not immediate 
hyperalgesia indicates that although the upregulation of PKA production is acute, its 
function is not critical for the initiation of a sensitized state. It appears likely that PKA 
instead acts to maintain sensitization through a downstream target.  The more sustained 
neuronal sensitization is likely due to CGRP-mediated activation of astrocytes and the 
increased expression of numerous cytokines that are known to promote a prolonged state 
of sensitization of both primary and second order neurons in the pain transmission 
pathway. My novel results provide direct evidence of bidirectional signaling within the 
trigeminal system, and hence challenge one of the long-standing dogmas in the pain field 
that peripheral sensitization promotes central sensitization.  However, this narrow view 
fails to explain how trigeminal nociceptive neurons become activated in the absence of 
any physical trauma or chemical-mediated inflammation in the peripheral tissues as is 
commonly reported in more chronic pain patients (often referred to as idiopathic pain).   
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  As with most studies, there are many unanswered questions that could be 
addressed to better understand the mechanism of action involved in CGRP-mediated 
sensitization of trigeminal neurons.  For example, does CGRP receptor activation couple 
to other intracellular pathways such as PKC and other MAP kinases such as p38 and 
JNK, which are associated with glial activation?  An obvious series of experiments would 
be to investigate the cellular changes within the spinal cord tissue and trigeminal 
ganglion in response to the PKA selective inhibitor KT 5720.  To test my hypothesis that 
glia are involved in the maintenance of sensitization, application of a glial inhibitor such 
as fluorocitrate might be used to observe changes in the length of sensitivity behaviorally.   
Another line of research could focus on using ELISAs to confirm the CGRP-mediated 
upregulation of individual cytokines such as IL-1β, IL-6, TNF-α, and Fractalkine, which 
are all known to play important roles in glial-maintained central sensitization (Ji et al., 
2013; Souza et al., 2013).  Initially I would study changes in the levels the pro-
inflammatory cytokine TNF-α since our laboratory recently has shown that intrathecal 
delivery of nicotine caused the greatest increase in the expression of the pro-
inflammatory cytokine TNF-α (Leung and Cahill, 2010). Elevated levels of TNF-α are 
associated with central sensitization and prolonged pain states(Kawasaki et al., 2008; 
Miller et al., 2009)  and similar to CGRP, elevated cytokine levels have been reported in 
serum and cerebrospinal fluid in migraine patients (Rozen and Swidan, 2007; Uzar et al., 
2011).  In the central nervous system, activation of p38 in glia due to TNF-α can lead to 
increased secretion of the pro-inflammatory cytokines IL-1 and IL-6 as well as ATP 
(Leung and Cahill, 2010). Additionally, TNF-α stimulates its own production in 
astrocytes via the CXCR4 receptor. This self-regulation leads to production of IL-1, IL-6, 
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ATP and nitric oxide, which are factors that contribute to enhanced neuronal activity and 
thus pathological pain.  Yet another possible avenue to pursue in future studies would be 
to determine if monoclonal antibodies directed against either CGRP or its receptor, which 
are currently being tested in human clinical trials, would block CGRP-mediated changes 
in peripheral trigeminal neurons and glia.  This is an interesting and important question 
since monoclonal antibodies cannot cross the blood brain barrier and hence could not 
directly block the stimulatory effect of CGRP within the upper spinal cord on primary 
neurons and glial cells.   Finally, having demonstrated that elevated levels of CGRP 
centrally can cause an increase in the coupling of neuronal cell bodies with satellite glial 
cells, which is implicated in the development of more chronic states (Durham and 
Garrett, 2010b), it will be of interest to identify the connexin proteins mediating this 
cellular communication via gap junctions.    
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